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3Background
• The IMM is expected to be a significant contributor to 
medical decision making in operational and planning 
processes for space flight missions
• NASA Standard 7009  requires that real world events 
be accurately represented by the model results to 
reach sufficient levels of validation
• For the IMM, this requirement is partially fulfilled by 
comparing the model’s predicted outcomes with 
observed mission data that has not been included in 
the model
Validation
• Model Validation
• “Substantiation that a computerized model within 
its domain of applicability possesses a satisfactory 
range of accuracy consistent with the intended 
application of the model”
• Schlesinger  et al. Terminology for model credibility. 
Simulation. 32 (3): 103-104
• Historical Data Validation
• “If historical data exist, part of the data is used to 
build the model and the remaining data are used to 
determine (test) whether the model behaves as the 
system does”
• Sargent. Verification and Validation of Simulation Models. 
Proceedings of the 2007 Winter Simulation Conference
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5Data Analysis
• Data on historical space flight missions were 
collected from mission medical records
• Data available for comparison included
• Total number of medical events
• The number of occurrences of each medical event
• Medical resource utilization
6Validation Approach
• Qualitative and quantitative approaches 
were used to compare historical data to 
model output
• Qualitative Approach
• Plots were created to visualize the differences 
between the model  and historical data
• Quantitative Approach
• Goodness of Fit (GoF) testing was chosen to 
test the null hypothesis that the predicted 
outcomes are statistically equivalent to the 
observed data
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Data Collection
• International Space Station (ISS) missions
• Increment medical debriefs by ISS crew surgeons
• ISS Private Medical Conference (PMC) Tool
• Space Shuttle Missions
• Mission medical debriefs by Shuttle crew surgeons
• Crew medical debriefs
• Surgeon logs 
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Simulation
• Model was run for seven ISS missions and fourteen 
Shuttle missions*
• Mission and crew profile was matched to historical 
mission data [# of crew, sex, mission length, and 
number of extravehicular activities (EVAs)]
• Each simulation was executed for 20,000 trials
* Data from these missions have not been used as input for 
the model
Analysis
Qualitative Approach
• Spider Plots
• Qualitatively assess the accuracy of IMM predictions for the 
total number of medical events
• Simultaneously  present the predicted and observed data for 
multiple missions
• Primarily for face validation
• Lacks formal statistical testing procedures
• Useful  in identifying potential discrepancies between the 
IMM and real-world events
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Analysis
Quantitative Approaches
• Chi-squared Goodness of Fit (GoF)
• May be utilized when the expected number of medical 
events is five or more (e.g. skin rashes, headaches)
• Reasonable test for the total number of medical events, 
specific medical conditions that occur frequently, and 
medical resource utilization
• The test statistic is calculated as:
• If the test statistic is greater than the critical value               , 
then the null hypothesis  that  the predicted outcomes are 
statistically equivalent  to observed data will be rejected
• An α = 0.05 level of significance was assumed for IMM GoF 
testing
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Analysis
Quantitative Approaches (Cont’d)
• Exact Probability Calculations
• When expected values for medical events are less than five, 
goodness of fit tests may be done using exact probability 
calculations
• The p-value is equal to the proportion of simulated trials 
where the number of events that occurred is equal to or 
more than the observed number
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Analysis
• Multiple Comparisons
• The alpha-level for statistical significance was 
determined using Bonferroni’s correction method 
• If N statistical tests were performed and the overall 
alpha was set at 0.05, then the final alpha level for 
any individual test was 0.05/N
• Example
• A single ISS mission with one crew member and 
83 medical conditions
• The alpha was 0.05/83 (0.0006)
• Therefore, p-values less than or equal to 0.006 
would be statistically significantly different
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Results
Total Medical Events - ISS Missions
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Mission Expected Observed Difference
1 12 7 5
2 18 14 4
3 18 13 5
4 14 10 4
5 15 14 1
6 17 16 1
7 19 23 -4
Average 16 14 2
Results
Total Medical Events
• ISS Missions
• Expected values overestimated the number of 
medical events for six of the seven missions
• The difference was not statistically significant      
(p = 0.36)
• The shape of the expected values is similar to the 
observed values
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Results
Spider Plot for ISS Missions
Total Number of Medical Events by Mission
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Results – Total Medical Events – Shuttle Missions
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Mission # of Crew Expected Observed Difference
1 6 24 26 -2
2 6 24 25 -1
3 6 24 22 2
4 7 28 27 1
5 6 25 31 -6
6 5 20 23 -3
7 6 26 28 -2
8 6 25 21 4
9 5 21 20 1
10 6 26 19 7
11 6 24 23 1
12 6 23 19 4
13 6 25 32 -8
14 6 24 21 3
Average 6 24 24 0
Results
Total Medical Events
• Shuttle Missions
• Expected values overestimated the number of 
medical events for eight missions
• Expected values underestimated the number of 
medical events for six missions
• The difference was not statistically different         
(p = 0.83)
• The shape of the expected values is similar to the 
observed values
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Results
Spider Plot for Shuttle Missions
Total Number of Medical Events by Mission
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Results
• Specific Medical Events
• 83 Medical conditions in the model
• GoF testing performed for all conditions 
individually
• Alpha level set at 0.0006 (0.05/83)
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Results
Specific Medical Events
• ISS Missions
• One medical condition was underestimated by the 
model (skin abrasion/laceration)
• Three medical conditions were overestimated by 
the model (hip sprain/strain, paresthesias,  and 
CO2 headache)
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Results
Specific Medical Events
• Shuttle Missions
• Five medical conditions were underestimated by 
the model (nasal congestion, hip sprain/strain, 
constipation, early insomnia, and CO2 headache)
• One condition was overestimated by the model 
(space motion sickness)
• Space adaptation headache and paresthesias 
were underestimated in some missions and 
overestimated in others
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Results
• Resource Utilization
• Only available for Shuttle missions
• Only pharmaceutical usage on Shuttle missions 
was reliably tracked
• There are 204 resources in the model
• The alpha level was set at 0.0002 (0.05/204)
• Ten pharmaceutical resources were 
underestimated by the model
• Eleven pharmaceutical resources were 
overestimated by the model
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Results – Resource Utilization
Pharmaceutical Resources Underestimated                 
on one or more simulations
23
Resource Overall p-value
Afrin 0
Ambien 0
Double Antibiotic Ointment 0
Dulcolax Suppository 0
Sonata 0
Bacitracin 1.51E-08
Triamcinolone Cream 4.5E-08
Aspirin 8.75E-07
Dulcolax Tablet 7.8E-06
Claritin 2.01E05
Results – Resource Utilization
Pharmaceutical Resources Overestimated                   
on one or more simulations
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Resource Overall p-value
Phenergan Tablet 1E-44
Tylenol 5.69E-32
Sudafed 7.43E-23
Phenergan Injectable 4.76E-21
Afrin 1.95E-17
Ibuprofen 2.17E-13
Milk of Magnesia 7.49E-07
Ambien 7.49E-07
Dulcolax Tablet 1.01E-05
Benadryl Capsule 1.42E-05
Povidone Iodine Swabs 1.71E-05
Discussion
• For both ISS and Shuttle missions, the total 
number of medical events expected was 
accurately predicted by the model
• For both ISS and Shuttle missions, specific  
medical events were forecast well by the 
model
• Shuttle medical resource utilization was well 
predicted by the model
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Limitations
• Limited number of ISS missions
• Missing or incomplete historical mission data
• Model baselined to ISS medical resources when 
analyzing Shuttle pharmaceutical utilization
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Conclusions
• This analysis provides strong evidence for the validity 
of the IMM in predicting medical event occurrences 
and resource utilization for ISS and Shuttle missions
• The model results were validated by historical 
mission data that have not been used in the model
• A small percentage of medical conditions and 
medical resource utilization were under or over 
predicted by the model
• These differences between model output and 
historical mission data can be used to improve model 
input data and the accuracy of predicted outcomes
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Questions?
